Monthly information on the total number of shares and voting rights in the share capital

Exosens reported strong Q3 2026 results with 23.5% revenue growth driven by increased demand and faster-than-expected capacity expansion. The company remains on track to meet its upgraded 2026 outlook and is supporting the deployment of next-generation nuclear technologies in the U.S. under the Department of Energy's Reactor Pilot Program.